New antibody approved for treatment of rheumatoid arthritis.
Adalimumab joins free existing biologic agents for the treatment of RA. Its place among these therapeutic options is unclear until head-to-head studies are performed with adalimumab and other biologic DMARDs. Adalimumab is currently in clinical trials for additional therapeutic uses, namely Crohn's disease and coronary artery disease.